X4 Pharmaceuticals XFOR - オプションチェーン

X4 Pharmaceuticals Inc ([symbol]) オプションチェーン

オプションコール

行使価格	買値	売値	前回の価格	中間価格	建玉	最終取引
2.50	1.15	4.30	0.00	2.725	0	-
5.00	0.00	3.00	0.05	0.05	5	-
7.50	0.00	0.05	0.00	0.00	0	-

個人投資家向けのプロ仕様のツール。

プレミアム

オプションプット

行使価格	買値	売値	中間価格	最終取引
2.50	0.00	3.00	0.00	-
5.00	0.65	4.20	2.425	-
7.50	1.00	6.00	3.50	-

銘柄コード	株価	出来高
GMHSGamehaus Holdings Inc	US$ 1.72 (83.27%)	11.93M
SMTKSmartKem Inc	US$ 0.51 (24.79%)	4.54M
ALPSALPS Group Inc	US$ 0.8439 (18.86%)	27.03k
SHMDSCHMID Group NV	US$ 5.95 (17.82%)	7.37k
OMHOhmyhome Ltd	US$ 0.8042 (16.10%)	4.97M
YXTYXT.COM Group Holding Ltd	US$ 0.351 (-35.36%)	1.32M
SCAGScage Future	US$ 0.646 (-23.38%)	18.05M
SUGPSU Group Holdings Ltd	US$ 0.77 (-22.66%)	700.93k
DLXYDelixy Holdings Ltd	US$ 0.405 (-18.18%)	1.79M
LBGJLi Bang International Corporation Inc	US$ 0.95 (-15.93%)	17.23k
SCAGScage Future	US$ 0.646 (-23.38%)	18.05M
GMHSGamehaus Holdings Inc	US$ 1.72 (83.27%)	11.93M
NOTVInotiv Inc	US$ 0.1422 (-14.39%)	11.6M
BGMSBio Green Med Solution Inc	US$ 1.6798 (11.99%)	6.84M
OMHOhmyhome Ltd	US$ 0.8042 (16.10%)	4.97M

銘柄コード

株価

出来高

SCAGScage Future

US$ 0.646

(-23.38%)

18.05M

GMHSGamehaus Holdings Inc

US$ 1.72

(83.27%)

11.93M

NOTVInotiv Inc

US$ 0.1422

(-14.39%)

11.6M

BGMSBio Green Med Solution Inc

US$ 1.6798

(11.99%)

6.84M

OMHOhmyhome Ltd

US$ 0.8042

(16.10%)

4.97M

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 2, 2026

BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on March 31, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the "2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 32,000 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.

The options have a ten-year term and an exercise price of $4.13 per share, which is equal to the closing price of X4’s common stock on March 31, 2026. Each option will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employee’s continued employment with X4 on such vesting dates. The options are subject to the terms and conditions of the 2019 Inducement Plan and the terms and conditions of an award agreement covering the grant.

About X4 Pharmaceuticals
X4 Pharmaceuticals is a company focused on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet needs. Leveraging expertise in diseases of the immune system and CXCR4 biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is commercially available in the U.S. as XOLREMDI® in its first indication. The Company is currently conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in chronic neutropenic disorders. The U.S. FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com.

Link article

$XFOR 🗞️